CL2017001638A1 - Productos farmacéuticos y composiciones líquidas estables de anticuerpos contra il-17 - Google Patents

Productos farmacéuticos y composiciones líquidas estables de anticuerpos contra il-17

Info

Publication number
CL2017001638A1
CL2017001638A1 CL2017001638A CL2017001638A CL2017001638A1 CL 2017001638 A1 CL2017001638 A1 CL 2017001638A1 CL 2017001638 A CL2017001638 A CL 2017001638A CL 2017001638 A CL2017001638 A CL 2017001638A CL 2017001638 A1 CL2017001638 A1 CL 2017001638A1
Authority
CL
Chile
Prior art keywords
liquid compositions
pharmaceutical products
antibodies against
stable liquid
refers
Prior art date
Application number
CL2017001638A
Other languages
English (en)
Inventor
Susanne Joerg
Kathrin Serno-Schersch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2017001638A1 publication Critical patent/CL2017001638A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA DIVULGACIÓN SE REFIERE A PRODUCTOS FARMACÉUTICOS Y COMPOSICIONES LÍQUIDAS ESTABLES DE ANTICUERPOS CONTRA IL-1 7 Y FRAGMENTOS DE UNIÓN AL ANTÍGENO DE ESTOS, POR EJEMPLO, A1N457 (SECUKINUMAB), YA PROCESOS PARA PREPARAR TALES PRODUCTOS FARMACÉUTICOS Y COMPOSICIONES. LA DIVULGACIÓN TAMBIÉN SE REFIERE AL USO DE ESTOS PRODUCTOS FARMACÉUTICOS Y COMPOSICIONES LÍQUIDAS (POR EJEMPLO, COMO PARTE DE UN KIT QUE CONTIENE INSTRUCCIONES PARA SU USO) PARA EL TRATAMIENTO DE VARIOS TRASTORNOS MEDIADOS POR IL-1 7 (POR EJEMPLO, TRASTORNOS AUTOINMUNITARIOS TALES COMO PSORIASIS, ESPONDILITIS ANQUILOSANTE, ARTRITIS PSORIÁSICA Y ARTRITIS REUMATOIDE).</p>
CL2017001638A 2014-12-22 2017-06-21 Productos farmacéuticos y composiciones líquidas estables de anticuerpos contra il-17 CL2017001638A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462095210P 2014-12-22 2014-12-22

Publications (1)

Publication Number Publication Date
CL2017001638A1 true CL2017001638A1 (es) 2018-04-13

Family

ID=55135471

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001638A CL2017001638A1 (es) 2014-12-22 2017-06-21 Productos farmacéuticos y composiciones líquidas estables de anticuerpos contra il-17

Country Status (27)

Country Link
US (2) US11801300B2 (es)
EP (2) EP3237001B1 (es)
JP (4) JP6770974B2 (es)
KR (3) KR102506173B1 (es)
CN (5) CN114452380A (es)
AR (1) AR103173A1 (es)
AU (1) AU2015370522B2 (es)
BR (1) BR112017013240A2 (es)
CA (1) CA2971800A1 (es)
CL (1) CL2017001638A1 (es)
CO (1) CO2017005950A2 (es)
DK (1) DK3237001T3 (es)
EA (1) EA033824B1 (es)
EC (1) ECSP17047155A (es)
FI (1) FI3237001T3 (es)
HR (1) HRP20240253T1 (es)
IL (3) IL310604A (es)
LT (1) LT3237001T (es)
MX (1) MX2017008412A (es)
PE (1) PE20170952A1 (es)
PH (1) PH12017500966A1 (es)
PT (1) PT3237001T (es)
RS (1) RS65387B1 (es)
SG (1) SG11201703828VA (es)
TN (1) TN2017000181A1 (es)
TW (1) TW201641104A (es)
WO (1) WO2016103153A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
EP3487881A1 (en) * 2016-07-19 2019-05-29 Novartis AG Methods of treating new-onset plaque type psoriasis using il-17 antagonists
TW202348250A (zh) * 2017-07-24 2023-12-16 美商再生元醫藥公司 穩定化之抗體組合物及其製法
WO2019087133A1 (en) * 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
CN111110842B (zh) * 2017-11-30 2020-12-11 百奥泰生物制药股份有限公司 一种治疗il-6相关疾病的人源化抗体的液体制剂
CN111303283A (zh) * 2018-12-12 2020-06-19 上海君实生物医药科技股份有限公司 抗il-17a抗体及其应用
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
RU2754760C2 (ru) * 2019-04-02 2021-09-07 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция анти-il17a антитела и ее применение
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
CN110124030A (zh) * 2019-06-10 2019-08-16 通化东宝生物科技有限公司 一种苏金单抗注射液及其制备方法
BR112022004941A2 (pt) 2019-09-20 2022-06-28 Novartis Ag Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
IL292926A (en) 2019-11-19 2022-07-01 Novartis Ag Methods for treating lupus nephritis using interleukin-17 (il-17) antagonists
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
CN117529506A (zh) * 2021-06-11 2024-02-06 海南先声药业有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
CN113999300B (zh) * 2021-12-13 2022-09-13 青岛润达生物科技有限公司 一种高效提取卵黄抗体的复合沉降剂及方法
CN114452383B (zh) * 2022-02-17 2023-06-06 中国中医科学院中药研究所 司库奇尤单抗在治疗糖尿病溃疡中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
NZ552959A (en) 1998-11-27 2008-06-30 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
EP1220682B1 (en) * 1999-10-04 2006-11-22 Novartis Vaccines and Diagnostics, Inc. Stabilized liquid polypeptide-containing pharmaceutical compositions
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
US7332276B2 (en) 2002-03-01 2008-02-19 Celltech R&D, Inc. Methods to increase or decrease bone density
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
ES2586401T3 (es) 2003-06-16 2016-10-14 Ucb Pharma S.A. Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
MX2007010971A (es) * 2005-03-08 2007-09-19 Pharmacia & Upjohn Co Llc Composiciones de anticuerpo anti-citla-4.
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2007117749A2 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies fpr treating cancer
WO2008133722A2 (en) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
EP2423226A3 (en) 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
NZ578235A (en) 2007-02-02 2012-05-25 Novartis Ag Modulators of sclerostin binding partners for treating bone-related disorders
DK2131860T3 (da) 2007-03-20 2014-01-13 Lilly Co Eli Anti-sclerostin-antistoffer
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
US20110044978A1 (en) 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
JP2012533548A (ja) * 2009-07-14 2012-12-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組成物における黄色形成および過酸化物形成を阻害する方法
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
KR101620771B1 (ko) * 2010-10-08 2016-05-12 노파르티스 아게 Ｉｌ―17 길항제를 사용하는 건선의 치료 방법
TWI616204B (zh) * 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
AU2012341081B2 (en) * 2011-11-21 2015-06-04 Novartis Ag Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
CN104159612B (zh) * 2012-03-07 2016-03-16 伊莱利利公司 Il-17抗体制剂
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations

Also Published As

Publication number Publication date
CO2017005950A2 (es) 2017-08-31
EP3237001A1 (en) 2017-11-01
AU2015370522A1 (en) 2017-06-01
HRP20240253T1 (hr) 2024-05-10
PH12017500966A1 (en) 2017-10-18
KR20230037677A (ko) 2023-03-16
JP2023113906A (ja) 2023-08-16
EP4372005A2 (en) 2024-05-22
CN114452380A (zh) 2022-05-10
JP2018502910A (ja) 2018-02-01
JP2020011963A (ja) 2020-01-23
CA2971800A1 (en) 2016-06-30
US11801300B2 (en) 2023-10-31
IL252141B (en) 2021-12-01
CN113855800A (zh) 2021-12-31
KR102614921B1 (ko) 2023-12-19
PT3237001T (pt) 2024-04-16
WO2016103153A1 (en) 2016-06-30
EP3237001B1 (en) 2024-02-07
US20170368174A1 (en) 2017-12-28
MX2017008412A (es) 2017-10-19
US20240173404A1 (en) 2024-05-30
KR20230173742A (ko) 2023-12-27
IL287328A (en) 2021-12-01
IL310604A (en) 2024-04-01
CN107257692A (zh) 2017-10-17
CN107257692B (zh) 2021-11-19
ECSP17047155A (es) 2019-02-28
AU2015370522B2 (en) 2018-05-10
BR112017013240A2 (pt) 2018-02-06
AR103173A1 (es) 2017-04-19
KR102506173B1 (ko) 2023-03-07
EA033824B1 (ru) 2019-11-29
IL287328B1 (en) 2024-03-01
KR20170095878A (ko) 2017-08-23
JP6770974B2 (ja) 2020-10-21
TW201641104A (zh) 2016-12-01
CN113876947A (zh) 2022-01-04
CN114452381A (zh) 2022-05-10
SG11201703828VA (en) 2017-07-28
IL252141A0 (en) 2017-07-31
RS65387B1 (sr) 2024-04-30
JP2021119165A (ja) 2021-08-12
PE20170952A1 (es) 2017-07-13
DK3237001T3 (da) 2024-04-15
JP6878524B2 (ja) 2021-05-26
TN2017000181A1 (en) 2018-10-19
LT3237001T (lt) 2024-04-25
EA201791422A1 (ru) 2017-10-31
FI3237001T3 (fi) 2024-03-22

Similar Documents

Publication Publication Date Title
CL2017001638A1 (es) Productos farmacéuticos y composiciones líquidas estables de anticuerpos contra il-17
CL2018000108A1 (es) Moléculas de anticuerpo que se unen a cd22
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
ZA201908214B (en) Anti-bcma heavy chain-only antibodies
CL2016001963A1 (es) Heteroarilos inhibidores de syk
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
EA201691582A1 (ru) Новые фармацевтические препараты
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
UA117289C2 (uk) Мультиспецифічне антитіло
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
MX2019015563A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
EA201692002A1 (ru) Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство
EA201590412A1 (ru) Композиции антител и их применения
EA201691541A1 (ru) Новые анти-baff антитела
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
EA201890572A1 (ru) Биофармацевтические композиции
MX369072B (es) Producto para el cuidado bucal y métodos para uso y fabricación de este.
EA201491471A1 (ru) Состав, содержащий антитело против ил-17
TR201902741T4 (tr) Kişisel Temizlik Bileşimleri
AU2015278731B2 (en) Fused triterpene compounds and uses thereof
EA201791845A1 (ru) Твердые формы менахинолов